Connect with us

Health

‘Dual-action’ weight-loss pill helps people drop 13% of body weight in three months in early trials

Published

on

‘Dual-action’ weight-loss pill helps people drop 13% of body weight in three months in early trials

An experimental weight-loss pill is showing promising results, helping people drop 13% of their body weight in a three-month period.

The results from early clinical trials were presented by Novo Nordisk — the Danish drugmaker behind Ozempic and Wegovy — at the European Association for the Study of Diabetes (EASD) annual meeting in Madrid this week.

The drug, amycretin, works by replicating two hunger hormones — amylin, which regulates appetite and creates a feeling of fullness, and glucagon-like peptide 1 (GLP-1), the same hormone that is used in Ozempic and Wegovy to suppress appetite and boost insulin secretion.

‘SIX-PACK SURGERY’ GAINING POPULARITY AMONG MEN, SAY PLASTIC SURGEONS

“Amycretin is the first treatment to harness the two distinct biological pathways stimulated by amylin and GLP-1 in a single molecule,” Martin Holst Lange, executive vice president and head of development at Novo Nordisk, said in a statement sent to Fox News Digital.

Advertisement

An experimental weight-loss pill is showing promising results, helping people drop 13% of their body weight in a three-month period. (iStock)

“We are proud to present the phase 1 study results at EASD, showing that the mean change in percentage body weight was -13.1% with amycretin after 12 weeks of treatment.”

While Ozempic and Wegovy are administered via injection, amycretin is given as a 50-milligram oral pill.

The clinical trial included participants who were obese or overweight but did not have diabetes. Those who took amycretin for 12 weeks lost more weight than those on a placebo — and higher doses led to more weight loss, according to Novo Nordisk.

OZEMPIC PUSH FOR SENIORS? SOME DOCTORS SAY MORE PEOPLE AGE 65 AND OVER SHOULD BE ON IT

Advertisement

Taking the pill once a day led to around 10% weight loss, and those who doubled the dose lost 13%.

Another benefit the researchers highlighted is that people taking amycretin did not appear to hit a “weight loss plateau,” continuing to shed pounds as long as they took it.

Novo Nordisk — the Danish drugmaker behind Ozempic and Wegovy — presented the findings at the European Association for the Study of Diabetes annual meeting in Madrid this week. (iStock)

“The lack of weight loss plateauing indicates the possibility of achieving further weight reductions with extended treatment,” Agnes Gasoirek, a senior clinical pharmacology specialist at Novo Nordisk, wrote in the study findings.

‘Dual effect’

Dr. Christine Ren-Fielding, director and chief of bariatric surgery at the NYU Langone Weight Management Program, commented on the drug’s effectiveness.

Advertisement

OBESITY MAKES PEOPLE MORE LIKELY TO CATCH COVID, STUDY SUGGESTS: ‘INDISPUTABLE RELATIONSHIP’

“GLP-1-based treatments, like Ozempic, have already shown impressive weight loss results by helping patients feel fuller for longer and reducing appetite,” the doctor, who was not involved in the study, told Fox News Digital. 

“Adding amylin, another hormone that plays a crucial role in regulating insulin and hunger signals, amplifies this effect.”

Adding amylin, a hormone that plays a crucial role in regulating insulin and hunger signals, amplifies the effect of GLP-1 drugs like Ozempic, a doctor said. (Reuters)

This “dual action” creates a more powerful tool to manage cravings and caloric intake, according to Ren-Fielding.

Advertisement

“It’s particularly interesting because it addresses weight management through multiple physiological pathways, making it more comprehensive and potentially more effective than conventional treatments that typically focus on a single mechanism,” she added.

Potential risks or side effects

The most commonly reported side effects of amycretin include gastrointestinal issues like nausea and vomiting, more so with higher doses, according to Novo Nordisk.

“These adverse effects are not unusual with GLP-1 receptor agonists, which are known to affect gastric motility,” Ren-Fielding noted. 

“It addresses weight management through multiple physiological pathways.”

It’s important to monitor these side effects closely, she advised, as GI issues are common among patients with obesity. 

Advertisement

“While the initial weight loss outcomes are indeed encouraging, further studies are needed to ensure that the therapeutic benefits consistently outweigh the potential risks, especially with long-term administration,” Ren-Fielding added.

‘Not a cure-all’

While GLP-1 based drugs — including this new experimental pill — may show promising results, Ren-Fielding emphasized that they’re “not a cure-all for obesity.”

      

“Obesity is a chronic, multifactorial disease that requires a comprehensive, long-term approach,” she told Fox News Digital.

“Pharmacological treatments can play a significant role in managing the condition, but they are often most effective when combined with other interventions.”

Advertisement

“Obesity is a chronic, multifactorial disease that requires a comprehensive, long-term approach,” a doctor told Fox News Digital. (iStock)

Some patients may benefit from surgical interventions, the doctor said, along with lifestyle changes such as regular exercise, healthy eating and psychological support to address underlying behavioral factors. 

“It’s important to recognize that obesity is not just about weight loss — it’s a lifelong condition that requires ongoing management, much like any other chronic disease,” she added.

Next steps

The results of the study are considered preliminary, as they have not yet been published in a peer-reviewed medical journal.

The researchers will continue to conduct research on amycretin in the coming months, according to Novo Nordisk.

Advertisement

CLICK HERE TO SIGN UP FOR OUR HEALTH NEWSLETTER

“The safety and tolerability profiles and the magnitude of weight loss support further development of amycretin, and we are awaiting data from the ongoing phase 1 trial with subcutaneous amycretin, with expected read-out in 2025,” Lange said.

“If further research supports these initial findings, I can envision it becoming a viable option for those struggling with obesity.”

Ren-Fielding said there is “certainly potential” for the new drug to get FDA approval, especially considering the effectiveness of GLP-1-based drugs in recent years — but confirmed that much more testing is needed. 

“The current clinical trials are promising, but we need larger, long-term studies to really assess the safety and overall benefits of the drug,” she told Fox News Digital. 

Advertisement

For more Health articles, visit www.foxnews.com/health

“If further research supports these initial findings, I can envision it becoming a viable option for those struggling with obesity,” she went on.

“While I’m cautiously optimistic, there’s still a road ahead before we see widespread availability.”

Health

Do collagen supplements really improve skin? Major review reveals the truth

Published

on

Do collagen supplements really improve skin? Major review reveals the truth

NEWYou can now listen to Fox News articles!

Collagen supplements have exploded in popularity, touted as everything from an anti-aging miracle to a muscle recovery booster.

But a sweeping new review conducted by U.K. researchers suggests that while collagen may help improve skin elasticity and ease arthritis pain, it does little for athletic performance or wrinkle reduction.

Researchers from Anglia Ruskin University analyzed 16 systematic reviews and 113 randomized controlled trials involving nearly 8,000 participants worldwide, which they say is the most extensive evaluation of collagen’s health effects to date. 

The review found consistent evidence that collagen supplementation improves skin elasticity and hydration over time and provides significant relief from osteoarthritis-related joint pain and stiffness, according to findings published in Aesthetic Surgery Journal Open Forum. 

Advertisement

A large U.K. review found that collagen supplements may improve skin elasticity and hydration over time. (iStock)

The researchers, however, did not find meaningful improvements in post-exercise muscle recovery, soreness or tendon mechanical properties (strength, springiness and stretch resistance).

“Collagen is not a cure-all, but it does have credible benefits when used consistently over time, particularly for skin and osteoarthritis,” co-author Lee Smith, professor of public health at Anglia Ruskin University, said in a statement.

EXPERIMENTAL SERUM SHOWS PROMISE IN REVERSING BALDNESS WITHIN 20 DAYS

“Our findings show clear benefits in key areas of healthy aging, while also dispelling some of the myths surrounding its use,” Smith added.

Advertisement

Collagen, the most abundant protein in the body, supports skin, bones, tendons, cartilage and connective tissue, according to experts. Natural collagen production begins to drop in early adulthood and declines more sharply with age.

The study found that collagen supplements may help reduce joint pain and stiffness in people with osteoarthritis. (iStock)

The review found that long-term collagen supplementation was linked to improved skin firmness and hydration, but did not help skin roughness — a proxy for visible wrinkles. 

Benefits appear to accumulate gradually, suggesting that collagen should not be viewed as an “anti-wrinkle ‘quick fix,’ but as a foundational dermal support for individuals seeking holistic skin maintenance,” the researchers said.

Advertisement

“If we define anti-aging as a product or technique designed to prevent the appearance of getting older, then I believe our findings do support this claim for some parameters,” Smith told the BBC. “For example, an improvement in skin tone and moisture is associated with a more youthful-looking appearance.”

Collagen supplementation was linked to reduced pain and stiffness in people with osteoarthritis, with stronger benefits seen over longer periods of use, and showed modest improvements in muscle mass and tendon structure that may support healthy aging. 

Collagen did not significantly improve skin roughness, a marker of visible wrinkles. (iStock)

However, it did not show meaningful results when used as a fast-acting sports performance supplement, and evidence for benefits related to cholesterol, blood sugar, blood pressure and oral health was mixed or inconclusive.

Dr. Daniel Ghiyam, a California-based physician and longevity specialist, said the findings align with what he sees in clinical practice.

Advertisement

CLICK HERE FOR MORE LIFESTYLE STORIES

“Collagen is a targeted support tool, not a foundation of health or performance,” Ghiyam, who was not involved in the study, told Fox News Digital. “When marketed that way, it makes sense. When marketed as a cure-all, it doesn’t hold up to the data.”

The authors noted that while many previous collagen studies have received financial support from the supplement industry, the current review did not receive industry funding.

Experts say collagen supplements may offer modest benefits for skin hydration and joint comfort, but they are not a cure-all. (iStock)

The team called for more high-quality clinical trials examining long-term outcomes, optimal dosages and differences between collagen sources, such as marine, bovine and plant-based alternatives. 

Advertisement

Among its limitations, the review could not determine whether certain forms of collagen work better than others or what the optimal regimen should be. 

TEST YOURSELF WITH OUR LATEST LIFESTYLE QUIZ

While the review included randomized controlled trials, the quality of the studies varied, with newer research generally showing stronger results.

Experts say more data and studies are needed to build on the findings. They also noted that diet plays a crucial role in skin health.

Collagen supplements, often sold as powders or pills, may improve skin elasticity and ease joint pain, experts say. (iStock)

Advertisement

Dr. Erum Ilyas, a Pennsylvania-based dermatologist and chair of dermatology at Drexel University College of Medicine, noted that the review analyzed previously published meta-analyses rather than generating new primary data.

CLICK HERE TO DOWNLOAD THE FOX NEWS APP

“At this time, I have not seen sufficiently strong independent evidence to routinely recommend collagen supplements to my patients,” Ilyas, who was not involved in the review, told Fox News Digital.

“Although some studies show modest improvements in markers such as hydration and elasticity, there remains limited independent, biopsy-confirmed evidence demonstrating sustained increases in dermal collagen content,” she added.

Fox News Digital has reached out to the researchers for comment.

Advertisement

Related Article

Cosmetic fillers can cause deadly complication, experts warn — but new tech exposes it
Continue Reading

Health

Origin of deadly cancer affecting young adults revealed in alarming report

Published

on

Origin of deadly cancer affecting young adults revealed in alarming report

NEWYou can now listen to Fox News articles!

As colorectal cancer (CRC) is now the leading cause of cancer death in adults under 50, a new report reveals some surprising shifts in the incidence of the disease.

Although rates of CRC have been declining among seniors, those 65 and under are facing a rise in diagnoses, according to a report titled Colorectal Cancer Statistics, 2026, from the American Cancer Society.

Adults 65 and younger comprise nearly half (45%) of all new colorectal cancer cases — a significant increase from 27% in 1995, states the report, which was published in CA: A Cancer Journal for Clinicians.

The disease is rising fastest among adults 20 to 49 years old, at a rate of 3% per year.

Advertisement

Colorectal cancer is now the leading cause of cancer death in adults under 50. (iStock)

Among adults 50 and under, 75% of colorectal cancers are diagnosed at an advanced stage. Half of the diagnoses in that age range are made between the ages of 45 and 49. Although that age group is eligible to receive routine screenings, just 37% do so.

CLICK HERE TO SIGN UP FOR OUR HEALTH NEWSLETTER

The report also revealed that rectal cancer is on the rise, now accounting for about one-third (32%) of all CRC cases — an increase from 27% in the mid-2000s.

CLICK HERE FOR MORE HEALTH STORIES

Advertisement

“After decades of progress, the risk of dying from colorectal cancer is climbing in younger generations of men and women, confirming a real uptick in disease because of something we’re doing or some other exposure,” said Rebecca Siegel, senior scientific director, surveillance research at the American Cancer Society and lead author of the report, in a press release.

Among adults 50 and under, 75% of colorectal cancers are diagnosed at an advanced stage. Half of the diagnoses in that age range are made between the ages of 45 and 49.  (iStock)

“We need to redouble research efforts to understand the cause, but also circumvent deaths through earlier detection by educating clinicians and the general public about symptoms and increasing screening in people 45-54 years.”

It is projected that 158,850 new cases of colorectal cancer will be diagnosed this year, and that the disease will cause 55,230 deaths, per the report.

CLICK HERE TO DOWNLOAD THE FOX NEWS APP

Advertisement

More than half of CRC cases can be linked to high-risk behaviors, the researchers said. Those include lack of nutrition, high alcohol consumption, smoking, lack of exercise and obesity.

“These findings further underscore that colorectal cancer is worsening among younger generations and highlight the immediate need for eligible adults to begin screening at the recommended age of 45,” said Dr. William Dahut, chief scientific officer at the American Cancer Society.

When the disease is caught at a local (early) stage, the five-year survival rate is 95%. (iStock)

“The report also shines a light on the crucial importance of continued funding for research to help discover new therapies to treat the disease and advance patient care.”

TEST YOURSELF WITH OUR LATEST LIFESTYLE QUIZ

Advertisement

When the disease is caught at a local (early) stage, the five-year survival rate is 95%, the report stated.

Related Article

Hidden virus inside gut bacteria linked to doubled colorectal cancer risk, study finds
Continue Reading

Health

Aging process could accelerate due to ‘forever chemicals’ exposure, study finds

Published

on

Aging process could accelerate due to ‘forever chemicals’ exposure, study finds

NEWYou can now listen to Fox News articles!

A new study suggests that middle-aged men may be more vulnerable to faster biological aging, potentially linked to exposure to “forever chemicals.”

The research, published in the journal Frontiers in Aging, examined how perfluoroalkyl and polyfluoroalkyl substances, more commonly known as PFAS, could impact aging at the cellular level.

PFAS are synthetic chemicals commonly used in nonstick cookware, food packaging, water-resistant fabrics and other consumer products, the study noted. 

Their chemical structure makes them highly resistant to breaking down, allowing them to accumulate in water, soil and the human body.

Advertisement

Chinese researchers analyzed blood samples from 326 adults enrolled in the U.S. National Health and Nutrition Examination Survey between 1999 and 2000.

A new study suggests that middle-aged men could face accelerated biological aging at the cellular level due to exposure to PFAS. (iStock)

The researchers measured levels of 11 PFAS compounds in participants’ blood and used DNA-based “epigenetic clocks” — tools that analyze chemical changes to DNA to estimate biological age — to determine how quickly their bodies were aging at the cellular level, the study stated.

CLICK HERE TO DOWNLOAD THE FOX NEWS APP

Two compounds, perfluorononanoic acid (PFNA) and perfluorooctanesulfonamide (PFOSA), were detected in 95% of participants.

Advertisement

Higher concentrations of those chemicals were associated with faster biological aging in men of certain age groups, but not in women.

“People should not panic.”

The compounds most strongly linked to accelerated aging were not the PFAS chemicals that typically receive the most public attention, the researchers noted.

CLICK HERE TO DOWNLOAD THE FOX NEWS APP

“The associations were strongest in adults aged 50 to 64, particularly in men,” Dr. Xiangwei Li, professor at Shanghai Jiao Tong University School of Medicine and the study’s corresponding author, told Fox News Digital. 

Advertisement

“While this does not establish that PFAS cause aging, it suggests that these widely present ‘forever chemicals’ may be linked to molecular changes related to long-term health and aging.”

The study found that two of the compounds were detected in 95% of participants, and higher levels were linked to faster biological aging in men ages 50–64. (iStock)

Midlife may represent a more sensitive biological period, when the body becomes more vulnerable to age-related stressors, according to the researchers.

Lifestyle factors, such as smoking, may influence biological aging markers, potentially increasing vulnerability to environmental pollutants.

Advertisement

While Li said “people should not panic,” she does recommend looking for reasonable ways to reduce exposure. 

That might mean checking local drinking water reports, using certified water filters designed to reduce PFAS, and limiting the use of stain- or grease-resistant products when alternatives are available.

CLICK HERE FOR MORE LIFESTYLE STORIES

Meaningful reductions in PFAS exposure will likely depend on broader regulatory action and environmental cleanup efforts, Li added.

The researchers noted that midlife could be a particularly sensitive stage, when the body is more susceptible to stressors associated with aging. (iStock)

Advertisement

Study limitations

The researchers outlined several important limitations of the research, including that the findings show an association, but do not prove that PFAS directly causes accelerated aging.

“The study is cross-sectional, meaning exposure and aging markers were measured at the same time, so we cannot determine causality,” Li told Fox News Digital.

The study was also relatively small, limited to 326 adults age 50 or older, which means the findings may not apply to younger people or broader populations.

TEST YOURSELF WITH OUR LATEST LIFESTYLE QUIZ

Researchers measured PFAS levels using data collected between 1999 and 2000, and today’s exposure patterns may differ.

Advertisement

Li added that while PFAS is known to persist in the environment and the body, these results should be validated through larger, more recent studies that follow participants over time.

Related Article

Nightly bathroom habit was missed sign of common men's cancer: 'I didn't know'
Continue Reading

Trending